ewings sarcoma_utsav

21
EWING’S SARCOMA By : Dr. Utsav Agrawal

Upload: utsav-agrawal

Post on 02-Jun-2015

319 views

Category:

Education


1 download

TRANSCRIPT

Page 1: Ewings sarcoma_UTSAV

EWING’S SARCOMA

By : Dr. Utsav Agrawal

Page 2: Ewings sarcoma_UTSAV

IntroductionEwing, in 1921 described it as a tumor occuring in

the diaphysis of long bone, in children, asso. With febrile attacks , anorexia and anaemia and which was radio-sensitive.

He believed it arose from endothelial elements of bone marrow and described it as diffuse endothelioma of bone

Willis found rosette formation and presence of primary lesion, usually in adrenals, in many cases

Ewings sarcoma is thought to be of either neuro-ectodermal or stem cell origin

All Ewings sarcoma’s are considered high grade malignancy and categorized under Enneking Stage II or III

Page 3: Ewings sarcoma_UTSAV

Epidemiology9% of primary bone sarcomas4th most common primary malignancy of bone but

2nd most common below 30yrs and most common below 10 yrs of age.

Age Group – 95% patients age between 5 to 30 yrs- of these most range between 5 to 15 yrs

• Sex - slight male prediliction – 60%• More common in Whites (95%)• No known predisposing factor• Chromosomal translocation – t(11;22)(q24;q12) leading to fusion of EWS and FLI gene. also t(21;22) and t(7;22)

Page 4: Ewings sarcoma_UTSAV

Clinical FeaturesPainSwellingFeverWeight lossAnemiaRaised ESR and CRPLeukocytosisAnd, symptoms depending on area of

involvement

Page 5: Ewings sarcoma_UTSAV

LocationCan develop in any bonePrincipally affects the lower segment of the skeleton in

more than 2/3 casesIn long tubular bones – proximal segment more

frequently involved than distal fragment (5:1 to 3:1) Usually of diaphyseal origin. Sometimes dia-metaphyseal. Rarely, metaphyseal.In vertebrae, most commonly involved – Sacrum Body is mainly affected with subsequent involvement of intra and para-spinal tissues and posterior elements mostly metastatic.• Rarely may be localized to soft-tissue or peri-osteum.

Page 6: Ewings sarcoma_UTSAV

10%

22 %

11%

F - 9%

8

126

1

3%

Page 7: Ewings sarcoma_UTSAV

RadiologyOn Plain X-ray – In long bones- Diaphyseal/metadiaphyseal Cortical erosion Periostitis Soft-tissue mass Osteolysis Aggressive nature with permeative/moth-eaten type of bone

destruction Peri-osteal response – may be lamellated (‘onion-skin’) or

hair-0n-end Cortical changes – longitudinal cross striations, tunnelling

and saucerization. Occasionally, osteosclerosis and pathological fractures

Page 8: Ewings sarcoma_UTSAV

Hair-on-end periosteal reaction

Onion skin formation

Page 9: Ewings sarcoma_UTSAV

Metatarsal involvement with moth-eaten appearance, periostitis Involvement of long bone with

lamellated appearance, saucerisation, cortical breach, periostitis

Page 10: Ewings sarcoma_UTSAV

Ewings sarcoma with extensive soft tissue involvement

Page 11: Ewings sarcoma_UTSAV

In Vertebrae – OsteolysisFracturesVertebra planaExtension to posterior segmentSoft tissue mass• In RibsOsteo-lytic/sclerotic/bothDirection of growth usually intrathoracicLarge extra-pleural mass

• Metastasis – Usually to Lungs(m.c.) and Bones.

Page 12: Ewings sarcoma_UTSAV

• Bone Scan - uptake - rarely cold spots• Gallium scan• CT scan – For extra-osseous and trans-articular spread - for chest metastasis - evaluation of response to therapy• MRI – for extra-osseous and intramedullary extent of

lesion - metastasis - pre-operative planning ( along with MR-angio) - response to therapy• PET scan• Biopsy

Page 13: Ewings sarcoma_UTSAV

Histo-pathologyDiaphyseal/dia-metaphysealPredominantly medullary, then extends to

haversian system and cortexGreyish-white to pink in colorsoft, friableOften of semi-liquid consistencyAreas of hemorrhage, necrosis and cyst

formation presentOnion-skin periosteal reaction

Page 14: Ewings sarcoma_UTSAV

MicroscopySmall round undifferentiated tumor cells with little

cytoplasm and indistinct bordersRound nuclei with stippled evenly distributed powder-

like chromatin and 1-2 nucleoliFrequent mitosisNecrosis and Ghost cellsMinimal inter-cellular substanceRosette and psuedo-rosette formationPeritheliomaNO GIANT CELLSPAS +ve presence of glycogenReactive for vimentin

Page 15: Ewings sarcoma_UTSAV

Ewings Family of Tumors1. Ewings2. PNET3. AskinsSimilarity between Ewings and PNET• C/f, radiology, light microscopy• Chromosomal translocation t(11:22)(q24:q12)• Reactivity towards p30/32 MIC-2 in 90%Differences : In PNET• More frequent epiphyseal involvement, Pathological fractures,

metastasis• Rosette formation• Electron microscopy – features of neural differentiation like dendritic

processes, abundance of cytoplasmic granules, intermediate filaments, neurosecretory granules and microtubule formation.

• Immunohistochemistry - +ve for neural markers – S-100, synaptophysin, NSE, neuro-filament protein.

Page 16: Ewings sarcoma_UTSAV

Differential diagnosisOsteosarcomaLymphomaLeukemiaOsteomyelitisPNET

Page 17: Ewings sarcoma_UTSAV

Prognostic factorsGood prognosis in – involvement of distal segment of extremities No metastasis Infants and young children FemalesPoor prognosis – Proximal segment involvement Sacral involvement Patients above 18 yrs LDH and ESR

Page 18: Ewings sarcoma_UTSAV

Enneking system for malignant tumors

Stage Grade Site Metastasis

IA Low G-1 Intracompartmental T1

-

IB Low G-1 Extracompartmental T2

-

IIA High G-2 Intracompartmental T1

-

IIB High G-2 Extracompartmental T2

-

III Any G Any T Regional/ distant metastasis

Page 19: Ewings sarcoma_UTSAV

TreatmentGoal – To eliminate tumor mass, prevent recurrence

and preserve functionDepends on Stage at presentation and Location of

lesionModalities of treatment – Chemotherapy, Surgery and

radiotherapyChemotherapy alone, as adjuvant or neo-adjuvant to

surgical excision or debulkingDrugs used – Vincristine, Actinomycin-D,

Cyclophosphamide ( VAC regimen)Also used - Doxorubicin, etoposide, ifosphamideRadiotherapy - Generally, a dose of 45-50 Gy is

administered over a 5 week course to treat local disease.

Page 20: Ewings sarcoma_UTSAV

Newer TherapiesNutlin – 3a MDM-2 antagonistFigitumumab – antibodies against IGF-R1mTOR inhibitors – everolimus, rapamycinRetinoids – FenretinideBiphosphonatesTRAIL receptor agonistsGene therapy

Page 21: Ewings sarcoma_UTSAV

THANK YOU